Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL5999968

CCC(c1ccc(OC)cc1)c1cccnc1.N

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.61
PDE4D Q08499 2/20 0.48
KCNA5 P22460 1/20 0.46
CYP19A1 P11511 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 2/20 0.42
CFTR P13569 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
GOPC Q9HD26 1/20 0.42
TBXAS1 P24557 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL5999698 0.85 CFTR (0.57) KCNA5KDM4ECFTRSLC6A2SLC6A4
Ammonia Solution, Strong SCHEMBL6000232 0.85 KCNA5 (0.56) CYP17A1PDE4DKCNA5CYP19A1KDM4E
SCHEMBL1944201 0.84 CFTR (0.59) KCNA5KDM4ECFTRSLC6A2SLC6A4
SCHEMBL658876 0.83 CFTR (0.57) PDE4DKCNA5CYP19A1KDM4ECFTR
Ammonia Solution, Strong SCHEMBL6000373 0.83 CFTR (0.46) PDE4DKCNA5CYP19A1KDM4EALDH1A1
Ammonia Solution, Strong SCHEMBL6000107 0.82 CYP17A1 (0.87) CYP17A1CYP19A1KDM4EALDH1A1KMT2A
SCHEMBL13871997 0.82 CYP17A1 (0.64) CYP17A1ALDH1A1KMT2A
Ammonia Solution, Strong SCHEMBL5999471 0.81 SLC6A4 (0.44) PDE4DKCNA5CYP19A1KDM4ECFTR
Ammonia Solution, Strong SCHEMBL6000489 0.81 CYP19A1 (0.60) PDE4DKCNA5CYP19A1ALDH1A1CFTR
Ammonia Solution, Strong SCHEMBL5999435 0.81 POLB (0.50) PDE4DKCNA5CYP19A1CFTRSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C CYP17A1 4384/4885PDE4D 3245/4885KCNA5 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.